We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Image of Laura Elizabeth Lansdowne

Laura Elizabeth Lansdowne

Managing Editor

Contact Us

As managing editor, Laura works closely with the editorial director to create, inform and maintain the overall editorial strategy for Technology Networks. She plays an active part in the general oversight and training of the in-house editorial team, as well as working directly with commissioned writers to produce content across the publication’s communities. After obtaining a first-class honors degree in biology, Laura worked as a quality assurance technologist before joining the Wellcome Sanger Institute and undertaking an additional qualification in clinical chemistry. In 2015, she left to pursue pharmaceutical and editorial-based roles, before joining Technology Networks in 2017.

Latest Content

Spatial Transcriptomics in Cancer

In this infographic, we explore spatial transcriptomics and how progress in this area is paving the way to a better understanding of cancer.

High-Throughput Screening

Download this infographic to explore key milestones and assay types, innovations driving high-throughput screening (HTS) and a typical HTS workflow.

Cancer Genetics

In this infographic, we delve into the field of cancer genetics, highlight key milestones and explore how genomic approaches are transforming diagnosis and treatment of the disease in the clinic.

Rewiring T Cells To Enhance Immunotherapy Efficacy

Researchers have identified a modifier gene called lymphotoxin beta receptor (LTBR) – which is not normally expressed in T cells – and combined it with CARs to create T cells that were better equipped at killing tumor cells.
Industry Insight

Cancer Research Horizons: Driving Innovation and Strengthening Academia–Industry Collaboration

In April 2022, Cancer Research UK unveiled Cancer Research Horizons, its new approach to driving innovation in the field. Technology Networks had the opportunity to speak with two members of Cancer Research Horizon’s executive leadership team to learn more about some of the cutting-edge experimental capabilities that will be used to interrogate cancer biology more thoroughly.

Opinionated Science Episode 43: Genomics Power Hour: Decoding Morning Sickness and Dog Behavior

In this episode of Opinionated Science, the team reviews two studies that show off the power of genomic technologies, from very different angles. One answers key questions about why some women experience extreme vomiting and sickness during pregnancy, and the other reveals why dog breeds aren’t all they are cracked up to be.


Skin Cancer Cells Depend on Alzheimer’s Protein To “Take Root” in the Brain

Researchers from NYU Grossman School of Medicine have discovered that skin cancer cells rely on amyloid beta (Aβ) to survive and thrive once they have metastasized to the brain.

Targeting Cancer Through Induced Viral Mimicry

Researchers from Sanford Burnham Prebys have been awarded two grants from the National Institutes of Health to study an emerging therapeutic strategy known as viral mimicry. Dr. Charles Spruck and colleagues are working to understand how a specific pathway silences endogenous retroviruses and retrotransposons selectively in breast cancer cells and whether this could expose a vulnerability that could be exploited.

The Placebo Response ‒ A Powerful Phenomenon

In a recent interview, Technology Networks had the pleasure of speaking with Professor Ted J. Kaptchuk, leading figure in placebo studies and a scholar of East Asian medicine, about the importance of humanistic dimensions of care, what is currently known about the neurobiology and genetics of placebo effects, open-label placebo studies and ethical use of placebos in clinical practice.
Industry Insight

Shielding Oncolytic Viruses From the Immune System To Improve Cancer Treatment

While oncolytic virus (OV) therapy has garnered increasing attention from the cancer research community, this therapeutic strategy doesn’t come without its challenges, as a patient’s immune system can sometimes mount a response to the OVs before they reach their intended target. To address this, Calidi Biotherapeutics has developed cell-based platforms to shield OVs from the immune system, so that they can effectively target and destroy the cancer cells.